Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Burden of Chronic Diseases
4.2.2 Increasing Use of Point-of-care (POC) Diagnostics Spurring the IVD Market
4.2.3 Increasing Government Healthcare Expenditure and Consumer’s Healthcare Spending
4.2.4 Advanced Technologies Fueling the IVD Market
4.2.5 Increasing Awareness and Acceptance of Personalized Medicine and Companion Diagnostics
4.3 Market Restraints
4.3.1 Lack of Proper Reimbursement
4.3.2 Stringent Regulatory Framework
4.3.3 Need For High Complexity Testing Centers
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Test Type
5.1.1 Clinical Chemistry
5.1.2 Molecular Diagnostics
5.1.3 Immuno Diagnostics
5.1.4 Haematology
5.1.5 Other Test Types
5.2 By Product
5.2.1 Instruments
5.2.2 Reagents
5.2.3 Other Products
5.3 By Usability
5.3.1 Disposable IVD
5.3.2 Reusable IVD
5.4 By Application
5.4.1 Infectious Diseases
5.4.2 Diabetes
5.4.3 Cancer/Oncology
5.4.4 Cardiology
5.4.5 Autoimmune Diseases
5.4.6 Nephrology
5.4.7 Other Applications
5.5 By End User
5.5.1 Diagnostic Laboratories
5.5.2 Hospitals and Clinics
5.5.3 Other End Users


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 F Hoffmann-La Roche AG
6.1.3 Becton, Dickinson and Company
6.1.4 Danaher Corporation
6.1.5 bioMerieux SA
6.1.6 Bio-Rad Laboratories Inc.
6.1.7 Thermo Fisher Scientific Inc.
6.1.8 Qiagen
6.1.9 Siemens Healthcare GmbH
6.1.10 Sysmex Corporation


7 MARKET OPPORTUNITIES AND FUTURE TRENDS